KALA BIO, Inc.
corporate_fare Company Profile
KALA BIO, Inc. (NASDAQ:KALA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for KALA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for KALA spans 8-K, DEF 14A, PRE 14A, 10-Q.
Recent high-impact activity:
- Nasdaq Panel Grants KALA BIO Continued Listing With $1.00 Bid Cure Deadlines
- KALA BIO Sets 1-for-30 Reverse Split, Trading Adjusted November 16
- KALA BIO Cuts Quarterly Net Loss ~90% to $0.8M, Ends Quarter With $7M Cash and No Debt
- KALA Bio Signs LOI to Acquire $12.7M-Revenue Telehealth Platform for $15M
- KALA BIO Sets November 3 Vote on Reverse Split Up to 1-for-300 to Regain Nasdaq Compliance
Financial Snapshot
Short Interest & Short Volume
1.81 days to coverFINRA reported short interest of 382,804 shares in KALA as of the October 30, 2026 settlement, a 29.0% decrease from the prior period — about 1.8 days to cover at its recent average daily volume. On November 13, 2026, 66.1% of KALA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for KALA, detected from its recent SEC filings · based on capital-structure filings through 2026-07-22.
$250M ATM Program Launched · Massive Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →